MINISO Group Holding Ltd vs Zimmer Biomet Holdings Inc — how do they compare? MINISO Group Holding Ltd trades at $9.16 (market cap $2.81B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 6.4× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays the higher dividend (7.12%). Which is the better fit depends on your goals.
| MNSO | ZBH | |
|---|---|---|
Market Cap | $2.81B | $17.97B |
Sector | Technology | Health |
52-Week High | $25.31 | $104.26 |
52-Week Low | $9.23 | $79.58 |
Enterprise Value | $3.68B | $25.04B |
Dividend Yield | 7.12% | 1.02% |
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.36, down 2.09% today, with mixed technical signals showing bearish moving averages but bullish oscillators including oversold RSI levels. Fundamentally, the company reported strong Q1 2026 earnings beat but missed expectations in three of the last four quarters. Revenue grew 22.4% YoY in H1 2026 to RMB 11.5 billion, driven by domestic China performance and store expansion, though overseas markets showed weakness. The company announced a HK$2 billion share repurchase program in June 2026 to support shareholder value.
The stock presents a value opportunity with attractive valuation multiples (P/E 15.25, P/S 0.82) below industry averages, supported by 60% analyst buy ratings and $11.05 consensus price target offering 18% upside. However, inconsistent earnings performance, competitive retail pressures, and overseas execution risks warrant caution. The oversold technical condition suggests potential near-term rebound potential if fundamental improvements materialize.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Trailing returns across standard periods
Latest headlines on both assets
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →